Literature DB >> 10960683

Neonatal estrogen blockade prevents normal callosal responsiveness to estradiol in adulthood.

H A Bimonte1, R H Fitch, V H Denenberg.   

Abstract

The rat corpus callosum (CC) is larger in males than females, and is responsive to hormone manipulations during development. We previously demonstrated that P25 ovariectomy (Ovx) enlarged (defeminized) adult CC, while P70 ovary transfer (OvT) counteracted this enlarging effect, resulting in smaller (feminized) CC. Since OvT females were not Ovx'd until P25, they received some neonatal estrogen (E) exposure. Behavioral data suggest that adult responsiveness to ovarian hormones depends upon prior organization by neonatal E. It has not been determined whether a similar phenomenon occurs for the feminization of brain morphology. The current experiment examined whether our previous finding of adult CC responsiveness to ovarian hormones depended upon neonatal E exposure. We investigated this by assessing the effects of P70 ovarian hormone replacement (via ovary transfer or E pellet) in females that received either (1) normal ovarian hormone exposure until P25 Ovx, or (2) the E receptor blocker tamoxifen from birth to P25 Ovx. Females receiving normal neonatal hormone exposure responded to P70 E in the female-typical manner: E reduced CC size. In contrast, females receiving neonatal E blockade responded to adult E in the opposite manner: E increased CC size. As far as we are aware, this is the first report suggesting that neonatal E exposure organizes the female brain so that it responds normally to the organizing actions of E when later exposure occurs. These findings further challenge the traditional model of female brain development, which asserts that normal female brain organization occurs by default, in the absence of gonadal hormone exposure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10960683     DOI: 10.1016/s0165-3806(00)00067-5

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  8 in total

1.  Proliferation and death of oligodendrocytes and myelin proteins are differentially regulated in male and female rodents.

Authors:  Mirela Cerghet; Robert P Skoff; Denise Bessert; Zhan Zhang; Chadwick Mullins; M Said Ghandour
Journal:  J Neurosci       Date:  2006-02-01       Impact factor: 6.167

2.  Pubertal ovarian hormone exposure reduces the number of myelinated axons in the splenium of the rat corpus callosum.

Authors:  M A Yates; J M Juraska
Journal:  Exp Neurol       Date:  2007-10-25       Impact factor: 5.330

3.  An update on the cognitive impact of clinically-used hormone therapies in the female rat: models, mazes, and mechanisms.

Authors:  J I Acosta; R Hiroi; B W Camp; J S Talboom; H A Bimonte-Nelson
Journal:  Brain Res       Date:  2013-01-16       Impact factor: 3.252

4.  Trajectories and phenotypes with estrogen exposures across the lifespan: What does Goldilocks have to do with it?

Authors:  Stephanie V Koebele; Heather A Bimonte-Nelson
Journal:  Horm Behav       Date:  2015-06-27       Impact factor: 3.587

5.  Increases in size and myelination of the rat corpus callosum during adulthood are maintained into old age.

Authors:  M A Yates; J M Juraska
Journal:  Brain Res       Date:  2007-01-20       Impact factor: 3.252

6.  Sexual dimorphism of oligodendrocytes is mediated by differential regulation of signaling pathways.

Authors:  Muthulekha Swamydas; Denise Bessert; Robert Skoff
Journal:  J Neurosci Res       Date:  2009-11-15       Impact factor: 4.164

7.  Early exposure to bisphenol A alters neuron and glia number in the rat prefrontal cortex of adult males, but not females.

Authors:  R N Sadowski; L M Wise; P Y Park; S L Schantz; J M Juraska
Journal:  Neuroscience       Date:  2014-09-01       Impact factor: 3.590

8.  Impact of in utero exposure to EtOH on corpus callosum development and paw preference in rats: protective effects of silymarin.

Authors:  Nicol Moreland; Linda La Grange; Rebecca Montoya
Journal:  BMC Complement Altern Med       Date:  2002-11-11       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.